Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain

  1. Isla, D.
  2. Lopez-Brea, M.
  3. Espinosa, M.
  4. Arrabal, N.
  5. Pérez-Parente, D.
  6. Carcedo, D.
  7. Bernabé-Caro, R.
Revista:
Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Ano de publicación: 2023

Volume: 21

Número: 1

Tipo: Artigo

DOI: 10.1186/S12962-023-00417-Z GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus